Nemluvio (Nemolizumab)

Nemolizumab is a humanized IgG1 monoclonal antibody that binds to the interleukin‑31 receptor A (IL‑31RA). By blocking IL‑31 signaling, it interrupts the pathway that drives itch and inflammation in the skin, leading to symptom relief.

The specific dose and dosing schedule of Nemluvio are determined by the prescribing clinician based on the patient’s medical condition, weight, and response to therapy. Patients should follow the prescriber’s instructions exactly.

Safety data for Nemluvio in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by the treating physician.

To request Nemluvio, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and any necessary import documentation.

Nemluvio targets the IL‑31 pathway, whereas many conventional systemic therapies (such as cyclosporine or methotrexate) act more broadly on immune function. Compared with topical steroids, Nemluvio offers a systemic approach that specifically reduces itch, but selection depends on disease severity, patient history and physician judgment.

Nemluvio must be stored in a refrigerator at 2‑8 °C. Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temperature excursions occur, consult the manufacturer’s guidelines before use.

Nemluvio is given as a subcutaneous injection, typically performed by a healthcare professional in a clinical setting. The injection is administered into the skin of the abdomen or thigh using a pre‑filled syringe or autoinjector, following aseptic technique.

Serious risks include hypersensitivity reactions such as anaphylaxis, severe infections due to immune modulation, and rare laboratory abnormalities like markedly elevated creatine phosphokinase. Patients should be monitored closely for any signs of these events and seek immediate medical attention if they occur.

Nemluvio is contraindicated in individuals with a known severe hypersensitivity to nemolizumab or any of its excipients. Caution is also advised for patients with active serious infections, uncontrolled cardiovascular disease, or those receiving live vaccines.